PSUSA/00002558/202501

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 14:00 (CET) to 18 November 2025, 15:00 (CET)

CAT quarterly highlights and approved ATMPs - December 2025

Opinion on medicine for use outside EU: Aluvia, lopinavir,ritonavir, HIV Infections, 21/09/2006 Positive opinion

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 65, Status: Authorised

Human medicines European public assessment report (EPAR): Pregabalin Sandoz, pregabalin, Date of authorisation: 19/06/2015, Revision: 23, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Ilumetri, tildrakizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0388/2024

Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Renal and urinary disorders, PIP number: P/0387/2024

Committee for Medicinal Products for Veterinary Use (CVMP): 2-4 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 2 December 2025 to 4 December 2025

Agenda of the CVMP meeting 2-4 December 2025